0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Pathology Quiz Case 2: Diagnosis FREE

Arch Otolaryngol Head Neck Surg. 2010;136(11):1148-1149. doi:10.1001/archoto.2010.199-b.
Text Size: A A A
Published online

Diagnosis: Primary signet ring carcinoma of the eyelid

Primary signet ring carcinoma of the eyelid is a unique malignant neoplasm that is derived from the sweat glands. It is an extremely rare tumor, with only 23 reported cases, excluding the one described herein.1A variety of names have been used to describe it, including eccrine sweat gland tumor of clear cell origin,2primary mucinous sweat gland carcinoma of the eyelid,3and histiocytoid variant of eccrine sweat gland carcinoma.4The variability in nomenclature reflects the tumor's debated histogenesis, with authors differing in opinion regarding an apocrine or eccrine origin. Despite the differences in terminology, the reported cases share a common morphological appearance, immunohistochemical profile, and clinical behavior. We have chosen to use the term primary signet ring carcinoma of the eyelid, which was recently coined in 2008.1

The tumor has been described only in the middle-aged and elderly, with patients ranging in age from 47 to 87 years. It also has a clear male predominance, as was shown in a recent study by Mortensen et al,1in which 18 of the 23 cases reviewed involved men. Although several cases, including the one described herein, presented as thickening of a single eyelid, the most common presenting feature is diffuse thickening of both upper and lower eyelids, which creates the appearance that the involved eye is squinting.1This feature has led some authors to dub it the monocle tumor.1The rate of disease progression is variable, in that the time from symptom onset to presentation to a physician ranges from 3 months to 5 years.5It has also been reported that the tumor may undergo a prolonged and indolent course, with a sudden, rapid progression.4Metastases at diagnosis are common. In the study by Mortensen and colleagues,1regional lymph node metastases were found in 30% of patients and involved preauricular, cervical, submandibular, and parotid nodes. Distant metastasis occurred in 17% of patients and involved the skin, spine, contralateral orbit, and lungs.1

Reports on imaging are limited. The findings of magnetic resonance imaging were reported in only 1 case, which describes the tumor as “a well-defined lesion from the right orbit to the periorbital skin.”6Swinson et al7reported a case involving a tumor that measured 15×10 mm on gross examination but was not highlighted by positron emission tomography. Kramer et al4described a patient with “nonspecific findings” on a computed tomographic scan of the head. To our knowledge, our case is the first one that describes the tumor as an enhancing soft-tissue lesion limited to the eyelid on magnetic resonance imaging.

Microscopically, the tumors consist of a diffuse or vaguely nodular infiltrate of single cells with hyperchromatic nuclei, prominent nucleoli, eosinophilic cytoplasm, and intracytoplasmic mucin, which creates the characteristic signet ring appearance that is seen in a few of the cells. The microscopic appearance is reminiscent of lobular carcinoma of the breast and signet ring carcinoma of the stomach. The immunohistochemical staining profile is consistent with the tumor's purported sweat gland derivation. Specifically, it shows reactivity with antibodies directed against gross cystic disease fluid protein 15, a marker of apocrine and breast epithelium.5Also, the cells show reactivity with antibodies against CK7, carcinoembryonic antigen, and epithelial membrane antigen.1,5Tumor cells show no expression of neuroendocrine markers such as synaptophysin and chromogranin.1Melanocytic markers, including S-100 protein, HMB-45, and melan-A, are not expressed, nor is CK20, although a CK20-positive tumor has been reported.6Estrogen receptor expression has been described in 3 cases, 2 of which showed concomitant progesterone receptor expression.4,5Two cases that showed a lack of expression of estrogen receptor and progesterone receptor have also been reported.1

The most important entity in the differential diagnosis is metastasis, especially from a lobular breast carcinoma or signet ring carcinoma of the intestinal tract. Gross cystic disease fluid protein 15 is useful evaluating these tumors, because, while it shows reactivity in signet ring carcinomas of breast origin and in primary signet ring carcinoma of the eyelid, it does not show reactivity for morphologically similar carcinomas of gastrointestinal tract or pulmonary derivation.8Staining with p63 is helpful in distinguishing most primary skin adnexal neoplasms, except mucinous carcinoma and apocrine carcinoma, from carcinoma that is metastatic to the skin.9Our case did not stain with antibodies against p63, and we are not aware of reports on p63 expression in this tumor type. However, because primary signet ring carcinoma of the eyelid is likely an apocrine tumor, the lack of staining is not surprising.

Apart from the case presented herein, to our knowledge there have been no reports on evaluation with antibodies against E-cadherin. Our case showed strong, diffuse expression of E-cadherin. Lobular breast carcinoma rarely expresses E-cadherin, and the exceptional positive cases tend to show focal staining that is limited to solid areas of the tumor.10E-cadherin may therefore be a useful marker in differentiating primary signet ring carcinoma of the eyelid from metastatic lobular breast carcinoma.

Signet ring carcinomas of the eyelid tend to be very aggressive and may invade the orbit to extensively involve the ocular adnexa. When possible, resection with negative margins is considered the treatment of choice. Orbital exenteration was required in 10 of the 19 reported cases (or 11 of the 20 cases, including ours) for which treatment data are available.1Several adjuvant treatments, including radiation, fluorouracil, and tamoxifen therapy, have been used.1Given the small number of cases, however, definitive recommendations for adjuvant treatment have not been made. In our case, we opted not to perform elective parotidectomy and selective neck dissection at the time of exenteration because we were planning to administer postoperative radiation to the primary site. Instead, we chose to expand the adjuvant radiation field to include these routes of possible lymphatic spread.

Long-term outcomes have been variable. In a review by Langel et al5that looked at long-term follow-up in 8 cases, 1 patient died of disease 26 months after treatment, 1 patient showed no evidence of disease 1.5 years after treatment, 3 patients were alive with disease between 4.5 and 6 years after treatment, and 3 patients died of other causes 10 years after treatment. Follow-up was not available on the remaining 2 patients.

In summary, primary signet ring carcinoma of the eyelid is a rare and distinct malignant neoplasm that occurs primarily in middle-aged and elderly men, is locally aggressive, and carries a significant risk of nodal and distant metastasis. It is important to rule out metastatic carcinoma to the eyelid from another site, especially the breast, before making a diagnosis. Treatment should be aimed at completely excising the tumor, which often requires orbital exenteration.

Return to Quiz Case 2.

Box Section Ref ID

Submissions

Residents and fellows in otolaryngology are invited to submit quiz cases for this section and to write letters to the Archivescommenting on cases presented. Quiz cases should follow the patterns established. See Instructions for Authors (http://archotol.ama-assn.org/misc/ifora.dtl).

Material for CLINICALPROBLEMSOLVING: PATHOLOGYshould be submitted electronically via the online submission and review system at http://manuscripts.archoto.com.

Reprints are not available from the authors.

REFERENCES

Mortensen  ALHeegaard  SClemmensen  OPrause  JU Signet ring cell carcinoma of the eyelid—the monocle tumour. APMIS 2008;116 (4) 326- 332
PubMed Link to Article
Rosen  YKim  BYermakov  VA Eccrine sweat gland tumor of clear cell origin involving the eyelids. Cancer 1975;36 (3) 1034- 1041
PubMed Link to Article
Thomas  JWFu  YSLevine  MR Primary mucinous sweat gland carcinoma of the eyelid simulating metastatic carcinoma. Am J Ophthalmol 1979;87 (1) 29- 33
PubMed
Kramer  TRGrossniklaus  HEMcLean  IW  et al.  Histiocytoid variant of eccrine sweat gland carcinoma of the eyelid and orbit: report of five cases. Ophthalmology 2002;109 (3) 553- 559
PubMed Link to Article
Langel  DJYeatts  PWhite  W Primary signet ring carcinoma of the eyelid: report of a case demonstrating further analogy to lobular carcinoma of the breast with a literature review. Am J Dermatopathol 2001;23 (5) 444- 449
PubMed Link to Article
Kiyohara  TKumakiri  MKouraba  STokuriki  AAnsai  S Primary cutaneous signet ring cell carcinoma expressing cytokeratin 20 immunoreactivity. J Am Acad Dermatol 2006;54 (3) 532- 536
PubMed Link to Article
Swinson  BRyan  FBarrett  AW  et al.  Histiocytoid eccrine sweat gland carcinoma of the eyelid: report of a case. Clin Exp Dermatol 2006;31 (6) 786- 789
PubMed Link to Article
Ivan  DNash  JWPrieto  VG  et al.  Use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from metastatic adenocarcinoma to skin. J Cutan Pathol 2007;34 (6) 474- 480
PubMed Link to Article
Sentani  KOue  NTashiro  T  et al.  Immunohistochemical staining of Reg IV and claudin-18 is useful in the diagnosis of gastrointestinal signet ring cell carcinoma. Am J Surg Pathol 2008;32 (8) 1182- 1189
PubMed Link to Article
Da Silva  LParry  SReid  L  et al.  Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol 2008;32 (5) 773- 783
PubMed Link to Article

Figures

Tables

References

Mortensen  ALHeegaard  SClemmensen  OPrause  JU Signet ring cell carcinoma of the eyelid—the monocle tumour. APMIS 2008;116 (4) 326- 332
PubMed Link to Article
Rosen  YKim  BYermakov  VA Eccrine sweat gland tumor of clear cell origin involving the eyelids. Cancer 1975;36 (3) 1034- 1041
PubMed Link to Article
Thomas  JWFu  YSLevine  MR Primary mucinous sweat gland carcinoma of the eyelid simulating metastatic carcinoma. Am J Ophthalmol 1979;87 (1) 29- 33
PubMed
Kramer  TRGrossniklaus  HEMcLean  IW  et al.  Histiocytoid variant of eccrine sweat gland carcinoma of the eyelid and orbit: report of five cases. Ophthalmology 2002;109 (3) 553- 559
PubMed Link to Article
Langel  DJYeatts  PWhite  W Primary signet ring carcinoma of the eyelid: report of a case demonstrating further analogy to lobular carcinoma of the breast with a literature review. Am J Dermatopathol 2001;23 (5) 444- 449
PubMed Link to Article
Kiyohara  TKumakiri  MKouraba  STokuriki  AAnsai  S Primary cutaneous signet ring cell carcinoma expressing cytokeratin 20 immunoreactivity. J Am Acad Dermatol 2006;54 (3) 532- 536
PubMed Link to Article
Swinson  BRyan  FBarrett  AW  et al.  Histiocytoid eccrine sweat gland carcinoma of the eyelid: report of a case. Clin Exp Dermatol 2006;31 (6) 786- 789
PubMed Link to Article
Ivan  DNash  JWPrieto  VG  et al.  Use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from metastatic adenocarcinoma to skin. J Cutan Pathol 2007;34 (6) 474- 480
PubMed Link to Article
Sentani  KOue  NTashiro  T  et al.  Immunohistochemical staining of Reg IV and claudin-18 is useful in the diagnosis of gastrointestinal signet ring cell carcinoma. Am J Surg Pathol 2008;32 (8) 1182- 1189
PubMed Link to Article
Da Silva  LParry  SReid  L  et al.  Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol 2008;32 (5) 773- 783
PubMed Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...